The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028
The acquisition sets up the foundation for a central hub of GMP value-added services and greater access to new customers in the rapidly growing Biopharma market
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio
CRL shall invest another Rs. 200 crore for creation of additional beds
Topiramate is indicated as a treatment of epilepsy and migraine
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Increases Siemens’ industrial software total addressable market by $11 billion; aligns with strategic goal to accelerate customer innovation across industries
The portfolio includes branded injectable cephalosporines for infectious diseases
Subscribe To Our Newsletter & Stay Updated
